ATLANTA--(BUSINESS WIRE)--MNG Laboratories is pleased to announce the launch of its most comprehensive clinical test ever, the MNGenome®.
The MNGenome® is the most clinically comprehensive genome on the market, offering clinicians additional analysis not found in other genome sequencing products. In addition to sequencing of nuclear genes, the MNGenome® will also include mtDNA deletion, depletion, and heteroplasmy analysis, as well as single nucleotide resolution CNV detection. Other innovations include the ability to detect repeat expansions, novel junctions associated with CNVs, and uniparental disomy. Trio and proband-only testing will be available.
“The addition of Illumina’s NovaSeq to our technology platform has allowed us to take genome sequencing to a new level,” noted MNG’s Chief Medical Officer, Dr. Peter L. Nagy, MD PhD. “In 2018 we will be able to offer our clients the most comprehensive diagnostic suite, by combining our new MNGenome®, our existing MNG Transcriptome™ and our upcoming methylome offering, we will be able to definitively inform as to whether a condition is of genetic origin.”
The MNGenome® can be used if other methods such as WES and CMA failed to provide diagnostic or prognostic insight into a patient’s condition, or suggest a therapeutic approach. MNGenome® will increase the probability of a correct diagnosis and suitable treatment options.
The MNGenome® includes:
- >99% of mappable regions of the genome are sequenced at >30X coverage
- Pathogenic SNV detection across the entire genome
- Mitochondrial sequencing, depletion, and deletion analysis with heteroplasmy assessment
- Single nucleotide resolution copy number analysis with junction identification
- Uniparental disomy detection
- Repeat expansion detection with confirmation by alternative technology
- Turnaround time of 2-6 weeks, STAT option of ≤2 weeks available
“Combined with our recently announced expanded global outreach, our launch of MNGenome® and other recent innovations in genetic testing put MNG in an excellent position for future growth,” noted MNG’s President and CEO, Terry Conrad. “Our focus on neurogenetics and leadership in biochemical testing make us a unique partner to clinicians, researchers, and drug developers in finding answers to rare neurological conditions.”
About MNG Laboratories
MNG Laboratories is an internationally recognized clinical diagnostic leader specializing in neurogenetic and complex biochemical testing. We are committed to a patient-centered testing menu, high-quality diagnostics, and first-in-class reporting driven by our Genome MaNaGer® analysis pipeline. Our Neurogenetic Answers™ reporting process helps us stay at the forefront of the evolving genetics field and our team-based approach to data interpretation ensures we provide a reliable, guideline compliant, short list of variants that cause or are likely to cause disease. Our comprehensive approach to diagnostics is accompanied by a team of customer support and scientific personnel available to answer your questions regarding our process, technology, and reports. With over 16 years of neurogenetic experience, and powered by a culture of discovery and advancement, MNG Laboratories delivers results that make a difference for patients and their families.
More information about MNG Laboratories can be found at mnglabs.com.